Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of SPG302 in Adults With Schizophrenia
Sponsor: Spinogenix
Summary
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Official title: A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2024-08-01
Completion Date
2026-03
Last Updated
2026-02-06
Healthy Volunteers
No
Conditions
Interventions
SPG302
small synthetic molecule
Placebo
Placebo
Locations (3)
CenExel CNS
Garden Grove, California, United States
Box Hill Hospital - Eastern Health
Box Hill, Victoria, Australia
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)
Melbourne, Victoria, Australia